Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.4K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K
Cancer Prevention02:59

Cancer Prevention

3.0K
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.

BJU international·2026
Same author

Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.

Annals of internal medicine·2026
Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026
Same author

Letter to the Editor: Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up.

European urology·2026
Same author

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.

European urology focus·2026
Same author

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

European urology·2026
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Evolving Recommendations on Prostate Cancer Screening.

Otis W Brawley1, Ian M Thompson1, Henrik Grönberg1

  • 1From the American Cancer Society, Emory University, Atlanta, GA; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Karolinska Institute, Stockholm, Sweden.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 2, 2016
PubMed
Summary
This summary is machine-generated.

Prostate-specific antigen (PSA) screening alone is insufficient for detecting aggressive prostate cancer. New tools like risk calculators, biomarkers, and MRI aim to improve early detection and treatment decisions for better patient outcomes.

More Related Videos

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

2.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

2.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Serum prostate-specific antigen (PSA) is an inadequate screening test for prostate cancer on its own.
  • Accurate screening is crucial to identify life-threatening prostate cancer requiring aggressive treatment.

Purpose of the Study:

  • To explore advancements in prostate cancer screening and diagnosis.
  • To highlight new technologies that improve the identification of high-grade prostate cancers and reduce false positives.

Main Methods:

  • Review of emerging technologies including the Prostate Cancer Risk Calculator (PCPTRC) version 2.0, Stockholm III (STHLM3) study utilizing plasma protein biomarkers, and multiparametric MRI.
  • Assessment of genomic tests for distinguishing treatable cancers from those needing observation.

Main Results:

  • PCPTRC 2.0 predicts cancer probability using PSA, age, race, family history, and physical findings.
  • STHLM3 combines biomarkers with clinical data for prostate cancer prediction.
  • Multiparametric MRI enhances tumor characterization and prediction of behavior.

Conclusions:

  • New technologies show promise for improving prostate cancer screening and diagnosis.
  • There is an urgent need for large-scale, high-quality studies to validate these emerging tests.
  • Shared decision-making between doctors and patients remains the standard of care until new technologies are proven.